: SOTAC · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Sotac Pharmaceuticals Ltd is an Indian pharmaceutical company incorporated in 2015 that specialises in the manufacturing and sale of a diverse range of therapeutic products. Its portfolio spans various categories including anti-diabetic, cardiac, anti-infective, and dermatological treatments.
The company generates revenue through the manufacturing and distribution of pharmaceutical formulations across multiple therapeutic segments. It operates as a manufacturer providing a broad spectrum of drugs, including antibiotics and chronic disease medications.
Growth is expected to be driven by the expansion of its diverse therapeutic portfolio and the increasing demand for both chronic and acute pharmaceutical treatments in the Indian market.
Unlock AI insights, financials, peers and live data on Sotac Pharma. and 5,000+ companies — free.
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sotac Pharma.SOTAC | ₹100 Cr | — | — | — | 18.0% | — | — | — |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Sotac Pharma.
: SOTAC · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Growth · Profitability · Valuation · Strength · Conviction
Sotac Pharmaceuticals Ltd is an Indian pharmaceutical company incorporated in 2015 that specialises in the manufacturing and sale of a diverse range of therapeutic products. Its portfolio spans various categories including anti-diabetic, cardiac, anti-infective, and dermatological treatments.
The company generates revenue through the manufacturing and distribution of pharmaceutical formulations across multiple therapeutic segments. It operates as a manufacturer providing a broad spectrum of drugs, including antibiotics and chronic disease medications.
Growth is expected to be driven by the expansion of its diverse therapeutic portfolio and the increasing demand for both chronic and acute pharmaceutical treatments in the Indian market.
Unlock AI insights, financials, peers and live data on Sotac Pharma. and 5,000+ companies — free.
As of Mar 2026